From: A national physician survey on prescribing syringes as an HIV prevention measure
 | Respondents (N = 588) | Non-Respondents (N = 1971) | Chi-square p-value |
---|---|---|---|
Gender | Â | Â | Â |
   Female | 29.8% (175) | 24.9% (491) | 0.01 |
Age (mean ± std) |  |  |  |
   Age: | 49.3 ± 11.2 | 51.1 ± 12.4 | 0.0009 |
Specialty | Â | Â | Â |
   Primary | 81.3% (478) | 85.6% (1687) | 0.0001 |
   Emergency Medicine | 12.9% (76) | 8.3% (164) |  |
   Specialist | 5.8% (34) | 6.1% (120) |  |
Region | Â | Â | Â |
   Northeast | 26.2% (152) | 24.7% (487) | 0.75 |
   South | 26.7% (155) | 28.8% (568) |  |
   Midwest | 23.2% (135) | 23.1% (455) |  |
   West | 23.9% (139) | 23.4% (461) |  |
Homestate syringe law | Â | Â | Â |
   Strict Prohibition | 27.0% (149) | 30.4% (599) | 0.12 |
   Access Intermediate | 40.1% (221) | 40.6% (800) |  |
   Open access syringe sales | 32.8% (181) | 29.0% (572) |  |
Syringe Exchange Program | Â | Â | Â |
   Legal SEP | 52.8% (309) | 50.0% (986) | 0.12 |
   SEP w/o claim to legal | 27.2% (159) | 26.1% (514) |  |
   No SEP operating | 20.0% (117) | 23.9% (471) |  |